We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

5 hedge funds and large institutions have $67.6K invested in ELITE PHARMACEUTICAL in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

51% less capital invested

Capital invested by funds: $138K → $67.6K (-$69.9K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
Geneva Advisors
Illinois
$52K – – –
JAFL
2
Jay A. Fishman Ltd
Michigan
$10.6K – – –
PCA
3
Personal Capital Advisors
California
$4K – – –
VWM
4
Valley Wealth Managers
New Jersey
$1K – – –
SBL
5
Sargent Bickham Lagudis
Colorado
$7 – – –

ELI Hedge Fund Activity: Q3 2016 in Review

5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2016, worth a combined $67.6K — down 51% from $138K a quarter earlier.

Fund positioning in ELI was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 5 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $67.6K of ELITE PHARMACEUTICAL stock for Q3 2016, down 51% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q3 2016 and 0 closed out.

Based on aggregated 13F filings for Q3 2016.